Navigation Links
Keryx Biopharmaceuticals, Inc. To Present at the Rodman & Renshaw Annual Global Investment Conference and To Hold Investor/Analyst Day
Date:8/31/2009

igator in numerous colorectal trials including capecitabine, oxaliplatin and bevacizumab (XELOX + AVASTIN(R)).

Discussing Zerenex Planned Phase 3 Program in Hyperphosphatemia:

Julia Lewis, M.D.

  • Professor of Medicine, Division of Nephrology, Vanderbilt University School of Medicine.
  • Dr. Lewis has participated in the design and execution of the IDNT Trial, the AASK Trial, the Cohort Study, and HEMO Study, as well as other important clinical trials.

The Investor/Analyst Day presentations will be audio webcast live, accessible from the Investor Information page of the Company's website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, a key signaling cascade that has been shown to induce cell growth and cell transformation. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types, with a Phase 3 in multiple myeloma, under Special Protocol Assessme
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Keryx Biopharmaceuticals Settles License Dispute With Alfa Wassermann
2. Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Multiple Myeloma
3. Keryx Biopharmaceuticals Inc. Regains Compliance With NASDAQ Listing Requirements
4. Keryx Biopharmaceuticals, Inc. Receives Extension for Nasdaq Listing Compliance
5. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
6. Keryx Biopharmaceuticals, Inc. Requests an Appeal Hearing After Receiving Notice of Delisting From Nasdaq
7. Keryx Biopharmaceuticals Receives Nasdaq Notification
8. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2008 Financial Results
9. Keryx Biopharmaceuticals KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2008 Financial Results on Tuesday, November 11, at 8:30 A.M. EST
11. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... The Wehrman Collaborative, LLC (WeCo) ... disabled users by disabled users, has granted use ... Educational Resources of Burnsville, Minnesota, for their ... the Minnesota Alliance for Patient Safety of Minneapolis, ... website. Both organizations have met WeCo’s Standards ...
(Date:10/25/2014)... Raleigh, NC (PRWEB) October 25, 2014 ... patient who continued to receive pemetrexed (Alimta), after his ... to read the full story , just posted on ... study from Uji Tokushukai Medical Center in Japan suggests ... for mesothelioma patients who cannot tolerate higher ...
(Date:10/25/2014)... FRIDAY, Oct. 24, 2014 (HealthDay News) -- Researchers ... say their findings are cause for concern. ... that are raised for human consumption contribute to ... health, according to background information from the study. ... germs sicken about 2 million people and kill ...
(Date:10/22/2014)... 2014 At a time when the ... and athletes at all levels, the UPMC Sports ... current discussion where two powerful messages are lost: Concussions ... result in full recoveries every day. , In striving ... fact and research, UPMC and the Concussion Program are ...
(Date:10/22/2014)... October 22, 2014 For Dr. Iris Hunter, ... money; it’s an extension of her life’s mission. Her extensive ... as the owner of FirstLight HomeCare, make it clear that ... to me that my work makes a difference in the ... entrepreneurial spirit, so after much research, I felt ready to ...
Breaking Medicine News(10 mins):Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 2Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 3Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Researchers Say Antibiotics in Fish a Health Concern 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 3Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 4Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2
... Medical,Inc. (Nasdaq: NXTM ), a leading manufacturer of ... a $50.0 million credit,and security agreement from a group ... Merrill Lynch Business Services Inc., for a term of,42 ... million term loan and a $20.0,million revolving credit facility. ...
... Research Hospital have discovered a new signaling molecule that ... body. The finding could lead to the development of ... such as Type 1 diabetes; and for inflammatory diseases, ... , The St. Jude team discovered that specialized immune ...
... Conn., Nov. 21 Therap Services will host ... 5-7, 2007 in,Southbury, Connecticut. The 2nd Direct Support ... Support Professionals who are daily,users of Therap as ... Therap,s users and its developers and support staff., ...
... survey found , WEDNESDAY, Nov. 21 (HealthDay News) -- Older ... stress, a new study shows. , A team of University ... 53 to 85 who worked at least 20 hours per ... male, 87 percent were white, about 8 percent were black, ...
... Nov. 21 Susan G. Komen for the ... breast cancer research and,community-based outreach programs, is accepting ... who lost a,parent to breast cancer., (Logo: ... Award helps students cover the costs of,tuition, books, ...
... Region activates when a friend,s voice calls, scientists say , ... they,ve spotted a brain region that selectively emphasizes certain sounds, ... person,s name. , Researchers from the University of Washington, Seattle, ... the experimental method they used to detect brain activity associated ...
Cached Medicine News:Health News:NxStage Medical Establishes $50 Million Credit Facility with a Group of Lenders Led by Merrill Lynch Capital 2Health News:NxStage Medical Establishes $50 Million Credit Facility with a Group of Lenders Led by Merrill Lynch Capital 3Health News:St. Jude finds molecule that could improve cancer vaccines and therapy for other diseases 2Health News:St. Jude finds molecule that could improve cancer vaccines and therapy for other diseases 3Health News:Therap Services to Host 2nd Conference for Direct Support Professionals 2Health News:Jobs Don't Stress Most Older Workers 2Health News:Susan G. Komen for the Cure Provides Scholarships for Students Who Lost a Parent to Breast Cancer 2
(Date:10/25/2014)... Burzynski Research Institute, Inc. (BRI) announced today that the ... company permission to conduct an open-label study of Antineoplastons ... age with a diffuse intrinsic brainstem glioma (DIPG). Study ... groups based on their age and whether or not ... study endpoint is a decrease in the size of ...
(Date:10/22/2014)...  Rescheduling of hydrocodone combination products (HCPs) will ... according to a new primary market research study ... research and consultation exclusively in the area of ... In August, the DEA ... from Schedule III to Schedule II status. This ...
(Date:10/22/2014)... BASKING RIDGE, N.J. , Oct. 22, 2014 ... (RMANJ), a world-renowned leader in the field ... more rapid approach to embryonic screening. The research ... American Society for Reproductive Medicine (ASRM) meeting in ... chromosome screening (CCS) and single gene defect (SGD) ...
Breaking Medicine Technology:Burzynski Research Institute, Inc. Announces FDA Permission to Launch a New Clinical Trial in Diffuse Intrinsic Brainstem Glioma 2Hydrocodone: Rescheduled, Repositioned & Reinvented 2Hydrocodone: Rescheduled, Repositioned & Reinvented 3New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 3
... 26, 2012  Richard Wolf Medical Instruments Corporation celebrates ... minimally invasive solutions that spare patients the costs ... (Logo:  http://photos.prnewswire.com/prnh/20120426/CG95191LOGO ) ... allowing doctors to visualize and access elusive sites ...
... April 26, 2012 - The Consumer Healthcare Products ... for signing into law House Bill 363, legislation ... implementing a drug offender registry, stricter penalties for ... stop-sale technology.  HB 363 and its companion legislation ...
Cached Medicine Technology:Richard Wolf Medical Instruments Corporation: 40 Years of Innovation 2
... 8F Percutaneous Vascular Surgical (PVS) System consists of ... Perclose Knot Pusher. The Prostar XL 8F PVS ... two pairs of sutured needles as well as ... precisely control the needles during deployment. the Perclose ...
... The new solid-state IRIS Medical IQ ... the treatment of retinal disorders and ... represents its latest technological innovation and ... Minimum Intensity Photocoagulation (MIP) procedures in ...
... The AIA-360 is a sophisticated Aumated Immunoassay Analyzer ... analyzer has a footprint of 16 X 16 ... Its compact design is ideal for physician ... testing, such as cardiac panels, as well as ...
... Solitaire represents the latest in green laser ... for use in both the operating room ... preference testing and the most experienced ophthalmic ... is the premium 532nm photocoagulator - unique ...
Medicine Products: